ロード中...
Modelling population-level impact to inform target product profiles for childhood malaria vaccines
BACKGROUND: The RTS,S/AS01 vaccine for Plasmodium falciparum malaria demonstrated moderate efficacy in 5–17-month-old children in phase 3 trials, and from 2018, the vaccine will be evaluated through a large-scale pilot implementation program. Work is ongoing to optimise this vaccine, with higher eff...
保存先:
| 出版年: | BMC Med |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6044028/ https://ncbi.nlm.nih.gov/pubmed/30001708 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12916-018-1095-6 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|